Background and Aims: Biosimilar infliximab CT-P13 offers the potential for large drug acquisition cost savings. However, there are limited published data regarding its efficacy, safety, and immunogenicity in inflammatory bowel disease [IBD], particularly in switching IBD patients from originator to biosimilar infliximab. We present the outcomes of a service evaluation of switching IBD patients established on originator infliximab to biosimilar, using a managed switching programme funded via a gain share agreement in a UK teaching hospital. Methods: Evaluation outcomes included drug persistence, changes in drug acquisition costs, patient-reported side effects, adverse events, patient outcomes assessed using the IBD-control Patient-Reported Outcome Measures [PROM] questionnaire, serum drug and antibody levels, and routinely collected biochemical markers. Results: A total of 143 patients with IBD [118 Crohn's disease, 23 ulcerative colitis, 2 IBD unclassified] were switched from originator infliximab to CT-P13. Patients reported a similar incidence of side effects before and after switch. No clinically significant differences were observed in mean C-reactive protein [CRP], albumin, haemoglobin levels, or platelet and white cell counts after the switch to CT-P13, whereas mean IBD-control-8 score improved from 10.4 to 11.2 [p = 0.041]. There was no significant difference in drug persistence between biosimilar and originator infliximab [p = 0.94] and no increase in immunogenicity was found. Drug acquisition costs decreased by £40,000-60,000 per month. Conclusions: A managed switching programme from originator infliximab to biosimilar CT-P13 in IBD, using a gain-share agreement, delivers significant cost savings and investment in clinical services while maintaining similar patient-reported outcomes, biochemical response, drug persistence, and adverse event profile.
Introduction
Biosimilars are biological medicines that were developed to be highly similar to originator or reference medicines and offer the potential of lower treatment cost. Biosimilar infliximab CT-P13 was the first infliximab biosimilar to be approved by the European Medicines Agency [EMA] in June 2013. 1 Through this regulatory approval process, CT-P13 [Remsima® and Inflectra®] and its reference medicine Remicade ® have been shown to have highly similar biological and therapeutic function, acknowledging that there are minor differences between the molecules─due to both the complex nature of these biological substances and the production methods. 2 CT-P13 has been approved for the same indications as the originator product, using data from randomised, controlled, double-blind clinical trials in rheumatoid arthritis and ankylosing spondylitis, which showed equivalent outcomes between originator infliximab and CT-P13. 3, 4 The EMA license for the use of CT-P13 in inflammatory bowel disease [IBD] was granted on the basis of extrapolation from the rheumatology data. To date, there are limited published data regarding the efficacy, safety, and immunogenicity of CT-P13 in IBD, particularly in the case of switching established patients from originator to biosimilar infliximab. [5] [6] [7] [8] [9] Given these uncertainties, the introduction of biosimilar infliximab [as with any new drug] must be done in a carefully controlled environment. This is especially true when patients who are doing well on an originator product are changed to a biosimilar.
The motivation for using biosimilars is the potential for large drug acquisition cost savings to the health economy, which in the UK would accrue to clinical commissioning groups; thus there is no direct incentive for care providers in the UK to switch patients. The majority of drug costs arise from patients on maintenance treatment rather than patients starting treatment. Although the evidence exists for switching established rheumatology patients to biosimilar infliximab, no such data existed in IBD. In order to realise these cost savings, a managed switching programme was developed to not only support patients through the process but also include a risk management plan, so that any problems within our IBD patients would be detected at the earliest opportunity. The managed switching programme was funded through a gain share agreement between the key stakeholders. Gain share is a collaborative arrangement between health care commissioners and providers in working together to create incentives that achieve both better outcomes for patients and greater efficiencies in the use of medicines which are not reimbursed via national prices. 10 The principle of gain share is to distribute the cost savings between the stakeholders, which incentivises secondary care providers to make the most efficient use of high-cost drugs and re-invest the cost savings in patient care such as local IBD services.
Here we present the outcomes of switching IBD patients established on originator infliximab to biosimilar infliximab, using a managed switching programme funded via a gain share agreement in a UK teaching hospital.
Method

Managed switching programme design
A managed switching programme was designed with input from all key stakeholders, including the local IBD patient panel, gastroenterologists, pharmacists, and the IBD nursing team, to support patients through this process and included a risk management plan [ Figure 1 ]. The patient panel is an open forum which is usually attended by 8-10 patients, who meet with the IBD clinical team every 6-8 weeks to provide patient perspective and input into the development of the local IBD service as well as research projects. The majority of the panel had received infliximab as part of their care. Through discussions, the panel understood the concept of biosimilars and also that infliximab was a high-cost drug. They expressed concerns about the gaps in the evidence base around the use of biosimilars in IBD and in particular the concept of switching patients. They were reassured by the increased monitoring patients would experience as part of the managed switching programme and the risk management aspects of the programme. Equally, they were keen to see part of the savings invested in developing the IBD service with a focus on dietitian support and specialist nurses.
Biosimilars were discussed at the gastroenterology departmental meeting; discussions focused on the scientific background of biosimilars, the published evidence, and the opportunity for the further development of the IBD service. It was stated very clearly by the consultant body that new investment in IBD services was required, given the lack of capacity within the existing IBD service to deliver the programme. There was unanimous agreement to the switching programme; key to this agreement was the reassurance provided by the risk management plan, which included robust pharmacovigilance procedures and the prevention of interchangeability by brand prescribing only.
A gain share agreement was agreed between University Hospital Southampton [UHS] NHS Foundation Trust and local clinical commissioning groups [CCGs] to: fund the managed switching programme; invest in the capacity of the nurse-led IBD biologics service to ensure the continued delivery of high quality cost-effective patient care in the face of rapidly rising biologics use in IBD; and develop an inpatient IBD nursing service. 11 All savings net of the investment in the IBD service were shared 50:50 between UHS and the CCGs. The agreed investment included a new band 7 IBD specialist nurse post, a 0.5 whole time equivalent [WTE] clerical post to support the service, a 0.2 WTE band 8 pharmacist and a 0.2 WTE band 6 dietitian, amounting to around 12% of the projected gross savings. It was agreed that the managed switching programme would start in April 2015, and all infliximab-treated IBD patients under the care of the adult IBD service were offered the opportunity to participate. Patients were switched to CT-P13 [Inflectra®, Hospira, UK] at the same dose and with the same frequency as originator infliximab.
Assessment of outcomes of programme
We conducted a service evaluation of the managed switching programme. The evaluation outcomes included drug persistence, changes in drug acquisition costs, patient-reported side effects, adverse events, a patient-reported outcome measure (the IBD Control Patient-Reported Outcome Measures [PROM] 12 ), infliximab trough
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On-going review at each infusion and antibody levels, and routinely collected blood tests including C-reactive protein [CRP], platelet count, haemoglobin, and albumin. Serum drug trough levels and anti-drug antibodies were measured using the Immundiagnostik IDK monitor enzyme-linked immunosorbent assay [ELISA] . Infliximab antibody concentration greater than 10 arbitrary units [AU]/mL was considered positive. Patients completed a questionnaire asking if they had any side effects since their last infusion of infliximab as well as the IBD Control PROM at each infusion. Any adverse events were reported using the Medicines and Healthcare Products Regulatory Agency [MHRA] Yellow Card Scheme. Data collection started before patients were switched to CT-P13 and at each subsequent infusion. Pharmacy dispensing records and CCG billing records were used to assess the financial impact of the switching programme. In order to assess drug persistence, the treatment outcomes of all IBD patients who were being treated with originator infliximab [one or more dose] on April 1, 2014 were compared with the outcomes of patients in the managed switching programme. If a patient stopped treatment, the reason for stopping was obtained from the patient's records.
All patients treated with at least one dose of biosimilar infliximab were included in the safety analysis. Outcomes were analysed in patients who provided relevant data at the time of the switch from originator infliximab to CT-P13 and after at least three infusions of CT-P13. Descriptive statistics were used to characterise patients' demographics, drug withdrawal rates, and adverse events. The statistical significance of difference between the IBD Control PROM score at baseline and at third dose of CT-P13 was assessed using Wilcoxon signed rank test; data were non-normally distributed. The differences in mean biochemical values and drug levels were measured using a paired Student's t test. Drug persistence was evaluated using survival curves for originator and biosimilar infliximab and compared using log-rank test. All two-sided p-values below 0.05 were considered significant. 
Results
Patients
Clinical outcomes
Laboratory values
In all, 126 patients had routine laboratory results available both before and at least after three doses of CT-P13. No significant differences were observed in mean CRP [5. Table 2 ].
Drug persistence
By April 2016, patients had received a median of 7 [range 1-9] infusions of CT-P13. Two patients were switched back to originator infliximab at the patient's request; one patient was on concomitant mercaptopurine and had abnormal liver enzymes with high 6-thioguanine [6-TG] and 6-methyl mercaptopurine [6-MMP] levels, and the second had non-specific flu-like symptoms.
Drug persistence is assessed in Figure 2 ; this shows the comparison between the cohort of all IBD patients at University Hospital Southampton who were being treated with originator infliximab from April 1, 2014 until March 2015, and the cohort of patients switched to CT-P13 from April 2015 to March 2016. The cohort treated with originator infliximab comprised 120 patients and was similar to the biosimilar cohort in terms of patient age, sex, phenotype, and disease duration [ Table 1 ]; 84 [70.0%] patients from the comparator originator infliximab group switched to CT-P13 from April 2015. There was no statistically significant difference in drug persistence between the originator infliximab cohort and the cohort of patients switched to CT-P13 [p = 0.94]. Similar reasons for originator infliximab and CT-P13 withdrawal are observed in Table 3 .
Safety
A total of 94 patients completed a questionnaire on adverse events both before the switch and at the third dose of CTP-13. The rates of adverse events are described in Table 4 . Most commonly reported side effects were joint pains [n = 24 before the switch and n = 13 after switch to CT-P13], headaches [n = 21 before the switch and n = 16 after switch to CT-P13], and infections [n = 17 before the switch and n = 13 after switch to CT-P13]. Figure 3 shows the number of vials of infliximab dispensed for IBD patients each month and the pass-through costs to our CCGs. This shows a rapid reduction in drug acquisition costs of between £40,000 and £60,000 per month after the switching programme was commenced in April 2015, despite an ongoing increase in the number of vials dispensed.
Drug acquisition costs
Discussion
We have described the early experience of a managed IBD infliximab switching programme, which successfully changed 143 patients from originator infliximab to biosimilar infliximab in a real-life NHS environment. Thus far, there does not appear to be any significant difference between the two infliximab products in terms of drug persistence, side effects, adverse reactions, disease activity, or blood tests, but ongoing follow-up is needed. It must be emphasised that continued close monitoring of this group of patients is essential given the relatively short clinical experience of using CT-P13 in IBD and the extrapolation of data by the EMA for the licensing of CT-P13 for IBD. We have demonstrated substantial cost savings to the health economy, part of which has been re-invested in not only delivering the programme but also improving the service and quality of care for the whole IBD patient population in Southampton, not just for biologics-treated patients. We acknowledge several limitations of the study. First, our patient cohort was very heterogeneous with regards to patient age, disease duration, and exposure to originator infliximab, but this would be expected of a real-life observational programme rather than a clinical trial. Second, we had complete data [IBD-Control-8 scores, safety questionnaires, and infliximab antibody and drug levels] on only a proportion of patients rather than the whole switch cohort; therefore differences in patient-reported outcomes, safety profile, and infliximab drug levels cannot be fully excluded. It is also worth noting that patients participating in the switching programme were monitored more closely than when on originator infliximab, and had more opportunity to report symptoms and side effects. We therefore postulate that an improvement in IBD-Control-8 score after the switch to CT-P13 may have been influenced by the increased monitoring and IBD specialist nursing support included in the switching programme. Finally, we recognise that standardised disease activity indices were not recorded. However, the IBD-Control VAS has been validated as a responsive tool to measure changes in patient status, and both the IBD-Control VAS and IBD-Control 8 have shown good correlation with the Physicians Global Assessment. 12 The absence of clinical trial data in IBD coupled with the new [to gastroenterologists] concept of biosimilars has led to a relatively slow and patchy uptake of biosimilars within the UK, despite the No., number. possible benefits to the health economy as a whole and the opportunity for improving IBD patient services using gain share agreements. This agreement has been key to the success of this programme by ensuring appropriate incentivisation of all the stakeholders including patients, care commissioners, care providers, and clinical gastroenterology teams. There was already a strong, trusting, patient-focused relationship between UHS and local CCGs, including the finance and pharmacy departments, based on the previous successful delivery of a gain share agreement around IBD biologics. This agreement invested in the nurse-led IBD biologics service, leading to significant improvements in patient safety and quality of care, recruitment to research studies, and significant cost savings, and as such it is possible to leverage the return on the investment of biosimilar savings into IBD patient services by developing robust data-driven biologics management systems. 11 The total investment in IBD services was £103,000 yearly or approximately 12% of the projected cost savings. This was felt to be reasonable by the IBD clinical team and the patient panel, given the work involved in delivering the programme, the financial environment of the NHS, and the needs of the clinical team at that time. It is important that the savings split within a gain share agreement between care commissioners and providers are net of the investment required to support the cost-saving activity. The absence of this investment in IBD services and therefore incentivisation of patients and IBD teams has been in part responsible for the slow uptake of biosimilar infliximab in some areas despite gain share agreements being in place.
The UHS IBD patient panel played a central role in the development of the switching programme. Many of this group have experience of infliximab, and so had a good understanding of the treatment area, and were supportive of the concept of switching after detailed discussions. They were therefore able to assist with the content of the information sheet that patients were given. 13 They were also clear that, as patients were taking the risk of switching [however small], specific investment in the IBD service caring for them was important, specifically dietitian resources and specialist nurses. Another step in the process was discussion with all the gastroenterology consultants using originator infliximab. Key to the acceptance of the switching of their patients to biosimilar infliximab, was the development of an understanding of the science and the regulatory processes behind biosimilars as well as the reassurance of a robust risk management system to minimise any potential risk to patients. They also recognised the opportunity to secure significant investment in the IBD service.
With new biosimilar infliximab products entering the market in the near future, there will be further reductions in the cost of infliximab. However, there is no evidence to support the use of biosimilars interchangeably and therefore substitution is not currently recommended.
14 The EMA appears to assume interchangeability between originator products and biosimilars, but it is unclear if this also applies between biosimilar products. The FDA view interchangeability as another level of evidence beyond biosimilarity; however, the evidence requirement for this to date has not been defined. 15 As part of the risk management strategy, a robust drug traceability system was put in place in the infusion unit in UHS as well as for inpatients who receive infliximab. With this, combined with brand name-only prescribing on the hospital electronic prescribing system and ongoing data collection and monitoring, we have thus far prevented interchangeability from occurring. Recent audit has confirmed complete adherence to these principles.
In conclusion, we have presented the development, implementation, and early outcomes of a successful managed switching programme, using a gain share agreement to ensure that all stakeholders were appropriately incentivised to allow significant service development while delivering significant savings to the health economy.
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